Gilead Made Gains In Oncology, Though Virology Remains King
New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
You may also be interested in...
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.